Results 201 to 210 of about 2,614,061 (283)

Predicting clinical pathways of traumatic brain injuries (TBIs) through process mining. [PDF]

NPJ Digit Med
Eili MY, Rezaeenour J, Roozbahani MH.
europepmc   +1 more source

Association of Patient, Physician, and Practice-Level Factors with Uptake of Payer-Led Oncology Clinical Pathways.

JAMA Netw Open, 2023
Mullangi S, Chen X, Pham T, Liu Y, Gordon AS, Debono D, Fisch MJ, Gönen M, Hershman DL.   +8 more
europepmc   +1 more source

Targeting TNBC: core–shell polycationic polyurea dendrimers with inherent anticancer activity

FEBS Open Bio, EarlyView.
Core–shell polycationic PURE dendrimers were tested in TNBC‐derived tumor models. Both formulations selectively targeted TNBC and effectively reduced tumor volume. PUREG4‐OEI48 suppressed tumor growth without detectable toxicity, whereas PUREG4‐OCEI24, despite showing efficacy, induced hepatic toxicity.
Adriana Cruz, Bruna Abreu, Cindy Mendes, Catarina Freitas‐Dias, Filipe Gonçalves, Fernanda Silva, José Ramalho, Saudade André, Vasco D. B. Bonifácio, Jacinta Serpa   +9 more
wiley   +1 more source

Primary Central Nervous System Tumors in Adolescents: A Population-Based Study on Epidemiology and Clinical Pathways in a Challenging Age Group. [PDF]

Curr Oncol
De Martino L, Piga P, Sessa M, Calì C, Russo C, Picariello S, Onorini N, Spennato P, Quaglietta L, Donofrio MV, Cinalli G, Vetrano F, Savoia F.   +12 more
europepmc   +1 more source

Establishment of a coculture system for Porphyromonas gingivalis and head and neck squamous cell carcinoma using spheroid culture and LATS inhibition

FEBS Open Bio, EarlyView.
We established a spheroid coculture system enabling viable Porphyromonas gingivalis–HNSCC interactions under normoxic conditions. Inhibition of LATS1/2 maintains tumor cells in an undifferentiated state, which may promote spheroid growth and create a more permissive environment for bacterial persistence.
Yurika Nakajima, Shogo Okazaki, Muneaki Tamura, Shuichi Sato, Kenichi Imai   +4 more
wiley   +1 more source

Specialist clinical pathways in audiology services for adults living with coexisting hearing loss and dementia: a scoping review protocol. [PDF]

BMJ Open
Wenje SM, Calvert S, Henshaw H, Spriggs RV, Dening T, Hendron E, Heffernan E.   +6 more
europepmc   +1 more source

Antibiofilm activity of a chionodracine‐derived peptide by NMR‐based metabolomics of cell‐free supernatant of Acinetobacter baumannii clinical strains

FEBS Open Bio, EarlyView.
KHS‐Cnd peptide is able to impair biofilm formation and disaggregate mature biofilms in Acinetobacter baumannii clinical isolates. Differences in extracellular metabolites reflect changes in biofilm metabolism due to KHS‐Cnd treatment. Among the differentially represented extracellular metabolites upon KHS‐Cnd treatment, the significantly altered ...
Fernando Porcelli, Enrico Landi, Francesco Maiurano, Irene Paris, Rosanna Papa, Marco Artini, Laura Selan, Stefano Borocci, Francesco Buonocore, Esther Imperlini   +9 more
wiley   +1 more source

WHO Workshop Report: Regulatory Science to Inform Clinical Pathways for Shigella Vaccines Intended for Use in Children in Low- and Middle-Income Countries. [PDF]

Vaccines (Basel)
Kaminski RW, Pavlinac PB, Platts-Mills JA, Rogawski McQuade ET, Hausdorff WP, Isbrucker RA, Vannice KS, Cavaleri M, Kochhar S, Mehring-LeDoare K, Enwere G, Wilder-Smith A, Kotloff KL, Sow S, Giersing BK.   +14 more
europepmc   +1 more source

Pathogenic Neurofibromatosis type 1 gene variants in tumors of non‐NF1 patients and role of R1276

FEBS Open Bio, EarlyView.
Somatic variants of the neurofibromatosis type 1 (NF1) gene occur across neoplasms without clinical manifestation of the disease NF1. We identified emerging somatic pathogenic NF1 variants and hotspots, for example, at the arginine finger 1276. Those missense variants provide fundamental information about neurofibromin's role in cancer.
Mareike Selig, Swanhild Lohse, Sara Elahi, Nils Hartmann, Stefanie Deckert, Shutian Si, Alexander Desuki, Anja Harder   +7 more
wiley   +1 more source

Development and validity testing of a matrix to evaluate maturity of clinical pathways: a case study in Saskatchewan, Canada. [PDF]

BMC Health Serv Res
Larson CL, Vanstone JR, Mise TR, Tupper SM, Groot G, Azizian AR.   +5 more
europepmc   +1 more source